Stockscreener 앱 받기
22.05
2.95%
-0.67
시간 외 거래:
22.03
-0.02
-0.09%
전일 마감가:
$22.72
열려 있는:
$23.02
하루 거래량:
316.54K
Relative Volume:
1.01
시가총액:
$754.39M
수익:
-
순이익/손실:
$-81.05M
주가수익비율:
-8.4058
EPS:
-2.6232
순현금흐름:
$-68.97M
1주 성능:
+1.94%
1개월 성능:
-11.41%
6개월 성능:
-9.67%
1년 성능:
+14.84%
1일 변동 폭
$21.95
$23.38
1주일 범위
$21.27
$23.38
52주 변동 폭
$15.47
$36.37
Arrivent Biopharma Inc Stock (AVBP) Company Profile
명칭
Arrivent Biopharma Inc
전화
240-780-6356
주소
18 CAMPUS BLVD., NEWTOWN SQUARE
AVBP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
22.05 | 793.72M | 0 | -81.05M | -68.97M | -2.6232 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Goldman | Buy |
| 2025-03-20 | 개시 | B. Riley Securities | Buy |
| 2025-03-10 | 개시 | Guggenheim | Buy |
| 2024-07-22 | 개시 | Oppenheimer | Outperform |
| 2024-04-30 | 개시 | H.C. Wainwright | Buy |
| 2024-02-20 | 개시 | Citigroup | Buy |
| 2024-02-20 | 개시 | Goldman | Buy |
| 2024-02-20 | 개시 | Jefferies | Buy |
모두보기
Arrivent Biopharma Inc 주식(AVBP)의 최신 뉴스
What drives ArriVent BioPharma Inc. stock priceExceptional stock performance - Jammu Links News
What analysts say about ArriVent BioPharma Inc. stockTurbocharged investment results - Jammu Links News
Is ArriVent BioPharma Inc. a good long term investmentTremendous growth potential - Jammu Links News
Is ArriVent BioPharma Inc. stock a growth or value playFree Capital Allocation Plans - Newser
P 500Low Risk Trade Timing Signals - Newser
60 Degrees Pharmaceuticals Secures $5 Million in Public Offering - AInvest
What makes ArriVent BioPharma Inc. stock price move sharplySafe Entry High Exit Alerts - Newser
Why ArriVent BioPharma Inc. stock attracts strong analyst attentionSolid Return Trade Selections - Newser
ArriVent BioPharma Conducts $75 Million Public Offering - Global Legal Chronicle
ArriVent BioPharma (NASDAQ:AVBP) Given a $33.00 Price Target by The Goldman Sachs Group Analysts - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Upgraded at The Goldman Sachs Group - Defense World
How To Trade (AVBP) - news.stocktradersdaily.com
ArriVent BioPharma stock rating resumed at Buy by Goldman Sachs - Investing.com Canada
Mintz Advises ArriVent BioPharma on $75 Million Underwritten Public Offering - Mintz
ArriVent BioPharma stock maintains Buy rating at Clear Street despite competitor approval - Investing.com Canada
ArriVent BioPharma Announces $75 Million Public Offering - The Globe and Mail
Latham & Watkins Advises on ArriVent’s US$75 Million Common Stock Offering and Pre-Funded Warrants - Latham & Watkins LLP
Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
ArriVent BioPharma's $75M Public Offering: A Necessary Dilution for Clinical Milestones - AInvest
ArriVent BioPharma Plans $75 Million Public Offering - MarketScreener
ArriVent BioPharma announces $75 million public offering By Investing.com - Investing.com UK
ArriVent BioPharma's $75M Offering: Navigating Dilution for Oncology's Next Breakthrough - AInvest
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Rating of “Buy” by Brokerages - Defense World
Research Analysts Offer Predictions for AVBP FY2025 Earnings - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Given Buy Rating at Guggenheim - Defense World
Latest Analyst Updates: June 24th, 2025 - The Globe and Mail
Clear Street initiates ArriVent BioPharma stock with Buy rating By Investing.com - Investing.com Canada
Citi ups ArriVent price target to $40, adding ‘upside 90-day short-term view’ - TipRanks
ArriVent BioPharma (AVBP) Presents Promising Firmonertinib Data in Lung Cancer Study | AVBP Stock News - GuruFocus
ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study - The Manila Times
ArriVent to Unveil Next Steps for Breakthrough EGFR PACC Lung Cancer Drug Firmonertinib - Stock Titan
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases New Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Shares Acquired by California State Teachers Retirement System - Defense World
Where are the Opportunities in (AVBP) - news.stocktradersdaily.com
Bank of America Corp DE Raises Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Millennium Management LLC Reduces Holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Comparing Immutep (NASDAQ:IMMP) and ArriVent BioPharma (NASDAQ:AVBP) - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Rating of “Buy” by Analysts - Defense World
Cencora Welcomes Lori J. Ryerkerk to Board of Directors - MyChesCo
BNP Paribas Financial Markets Decreases Stock Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 1,327 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Promising Outlook for ArriVent BioPharma: Buy Rating Justified by Upcoming EGFR PACC Mutant NSCLC Program Updates - TipRanks
Deutsche Bank AG Boosts Stock Position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.5% – Here’s What Happened - Defense World
Wall Street Zen Upgrades Atea Pharmaceuticals (NASDAQ:AVIR) to “Hold” - Defense World
Wall Street Zen Downgrades ArriVent BioPharma (NASDAQ:AVBP) to Strong Sell - Defense World
ArriVent BioPharma (NASDAQ:AVBP) Coverage Initiated at Jones Trading - Defense World
JonesResearch Begins Coverage on ArriVent Biopharma (AVBP) with - GuruFocus
ArriVent BioPharma (AVBP) Coverage Initiated with 'Buy' Rating | - GuruFocus
JonesResearch Begins Coverage on ArriVent Biopharma (AVBP) with Optimistic Outlook | AVBP Stock News - GuruFocus
Northern Trust Corp Purchases 10,498 Shares of ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
Arrivent Biopharma Inc (AVBP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.59%
0.34%
자본화:
|
볼륨(24시간):